Inactive Instrument

NicOx SA Share Price Euronext Paris

NCOX

FR0000074130

News in other languages : NicOx SA

27/08	Bourse : Pernod Ricard au régime sec, méthode Coué chez Stellantis, la tech américaine se rebiffe
27/08	La FDA rendra sa décision sur le NCX 470 de Nicox d'ici fin avril prochain
27/08	Nvidia, est-ce que ça suffira ?
27/08	Nicox annonce avril 2027 comme date PDUFA pour NCX 470 dans le traitement du glaucome
10/08	Bourse : Innate signe avec SOBI, Apple se tourne vers CXMT

More news

Managers and Directors : NicOx SA

Manager	Title	Age	Since
Gavin Spencer CEO	Chief Executive Officer	55	28/02/2024
Sandrine Gestin DFI	Director of Finance/CFO	58	01/01/2015
Doug Hubatsch CTO	Chief Tech/Sci/R&D Officer	-	13/12/2021

Director	Title	Age	Since
Gavin Spencer BRD	Director/Board Member	55	08/04/2024
Damian Marron CHM	Chairman	64	16/07/2024
Marc Bozec BRD	Director/Board Member	-	16/07/2024

More insiders

Specialty & Advanced Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NICOX SA	-7.95%	-9.39%	-	-	3.94Cr
MERCK & CO., INC.	-0.40%	-1.92%	+75.65%	+35.58%	37TCr
MERCK KGAA	-0.89%	+0.43%	+27.87%	-16.27%	7.08TCr
HALOZYME THERAPEUTICS, INC.	+1.08%	-1.98%	+45.20%	+150.21%	1.2TCr
KYOWA KIRIN CO., LTD.	+1.77%	+3.70%	+2.67%	+0.15%	871.75Cr
SK BIOPHARMACEUTICALS CO., LTD.	-0.80%	+4.30%	-11.46%	+0.92%	500.03Cr
YUHAN CORPORATION	-1.41%	+1.70%	-26.26%	+21.05%	459.34Cr
BETTA PHARMACEUTICALS CO., LTD.	-0.14%	-1.37%	-28.57%	+2.92%	316.11Cr
SUPERNUS PHARMACEUTICALS, INC.	+1.10%	-2.00%	-0.74%	+38.85%	254.19Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-2.27%	-3.75%	-17.97%	-14.26%	207.92Cr
Average	-0.99%	-0.04%	+7.38%	+24.35%	5.28TCr
Weighted average by Cap.	-0.41%	-2.03%	+63.01%	+29.17%

See all sector performances

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is bimatoprost grenod (NCX 470), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox SA generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the United States, and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Employees

Sector

Pharmaceuticals

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	3.43Cr 3.98Cr 3.22Cr 2.94Cr 5.52Cr 378.86Cr 5.56Cr 38Cr 15Cr 192.11Cr 15Cr 15Cr 636.11Cr	P/E 2026 *	-5.56x	P/E 2027 *	38.9x
Enterprise Value	3.43Cr 3.98Cr 3.22Cr 2.94Cr 5.52Cr 378.86Cr 5.56Cr 38Cr 15Cr 192.11Cr 15Cr 15Cr 636.11Cr	EV / Sales 2026 *	11.4x	EV / Sales 2027 *	3.43x
Free-Float	99.65%	Yield 2026 *	-	Yield 2027 *	-

27/08	The FDA will issue its decision on Nicox's NCX 470 by the end of next April
27/08	US FDA to Complete Nicox's Glaucoma Drug Review by April 2027	MT
27/08	Nicox S.A. Announces U.S. Food and Drug Administration Accepts the New Drug Application for NCX 470	CI
10/08	Nicox Sa and Ocumension Therapeutics Submit Ncx 470 New Drug Application in China	CI
10/08	Nicox Partner Files China Drug Application for NCX 470 Eye Drop	MT
10/08	A Nicox partner has cleared an important milestone in China
01/07	Nicox Submits NCX 470 New Drug Application In The United States	CI
01/07	Nicox files U.S. marketing approval application
23/06	Nicox Bags EUR6 Million Shareholder Loan	MT
23/06	Nicox Secures Backing From a Shareholder and Financial Partner
18/06	Nicox Receives Positive Feedback from China
18/06	Nicox Announces Positive Pre-Submission Regulatory Feedback in China Supporting NDA Filing for NCX 470	CI
30/04	Nicox S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

27/08	Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma	GL
10/08	Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension	GL
01/07	Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment	GL
23/06	Nicox and Vester Finance Sign Shareholder Loan Agreement to Support Strategic Activities for the Company	GL
18/06	Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470	GL

	2026 *	2027 *
Net sales	30L 34.84L 28.17L 25.71L 48.31L 33Cr 48.65L 3.34Cr 1.3Cr 17Cr 1.31Cr 1.28Cr 56Cr	1Cr 1.16Cr 93.9L 85.71L 1.61Cr 110.51Cr 1.62Cr 11Cr 4.33Cr 56Cr 4.36Cr 4.27Cr 185.55Cr
Net income	-60L -69.69L -56.34L -51.43L -96.61L -66Cr -97.3L -6.68Cr -2.6Cr -34Cr -2.62Cr -2.56Cr -111.33Cr	10L 11.61L 9L 9L 16.1L 11Cr 16.22L 1.11Cr 43.29L 5.6Cr 43.61L 42.66L 19Cr
Net Debt	-	-

NicOx SA Share Price Euronext Paris

Stocks

NCOX

FR0000074130

Pharmaceuticals

Valuation : NicOx SA

Latest news : NicOx SA

Press Releases : NicOx SA

News in other languages : NicOx SA

Quotes and Performance

Managers and Directors : NicOx SA

Specialty & Advanced Pharmaceuticals

Financials

Company Profile